Bioengineered vaccine shows efficacy at protecting mice from COVID-19
Researchers have developed a novel vaccine using nucleotide untranslated regions that successfully protected mice from COVID-19.
List view / Grid view
Researchers have developed a novel vaccine using nucleotide untranslated regions that successfully protected mice from COVID-19.
A team has found that a mutation in the ATAXIN-1 gene causes spinocerebellar ataxia type 1 (SCA1), presenting a drug target for the condition.
Drug Target Review rounds up some of the latest news in COVID-19 vaccine candidate R&D.
The third phase of the ENCODE project has been released, with new information on genes and their potential regulators in their respective genomes.
Researchers have revealed that the microRNA miR-218-5p promoted hair growth in mice, so is a promising drug target for hair loss.
The vaccine candidate repRNA-CoV2S elicited both antibody and T cell responses after just two injections in mice and macaques.
A study has shown that p53 rewires RNA splicing which leads to further activation of the KRAS oncogene, presenting a target for the progression of pancreatic cancer.
In lab conditions, a new biomaterial was able to accelerate bone regeneration by boosting an immune response that encourages repair.
Non-invasive imaging has played an increasing role in drug discovery and development processes. Nikki Withers spoke with Yochi Slonim, who discusses a novel technology that leverages FRET signals for the discovery of small molecule drugs that selectively control mRNA translation in a novel target space.
The articles in this in-depth focus discuss the difficulties in deciding what information to capture when imaging three-dimensional (3D) cell models and the use of non-invasive imaging techniques to discover small molecule drugs to control protein translation.
Post-infection genome editing could be the cause of mutations in the SARS-CoV-2 virus responsible for the COVID-19 pandemic, driving its evolution.
A MERS vaccine, which uses RNA-based adjuvants, has demonstrated efficacy in non-human primates and is now being developed as a prophylactic for COVID-19.
A molecule called microRNA-744, which influences inflammation, has been revealed by researchers as a new drug target for Sjögren's Syndrome.
A group of researchers has used cryo-EM to discover the structure of the remdesivir-bound RNA complex of SARS-CoV-2 and explain how the drug inhibits COVID-19 viral replication.
A new study has revealed that less than 10 percent of respiratory and intestinal cells are susceptible to SARS-CoV-2 infection and expression of ACE2 receptors is driven by the body's immune response.